<DOC>
	<DOCNO>NCT00519285</DOCNO>
	<brief_summary>Primary objective demonstrate overall survival improvement aflibercept compare placebo patient receive docetaxel / prednisone metastatic androgen-independent prostate cancer ( MAIPC ) . The secondary objective : - To assess efficacy aflibercept compare placebo parameter prostate-specific antigen ( PSA ) level , cancer relate pain , progression free survival ( PFS ) , tumor-based skeletal event health-related quality life ( HRQL ) ; - To assess overall safety treatment arm ; - To determine pharmacokinetics intravenous ( IV ) aflibercept population ; - determine immunogenicity IV aflibercept .</brief_summary>
	<brief_title>Aflibercept Combination With Docetaxel Metastatic Androgen Independent Prostate Cancer</brief_title>
	<detailed_description>The study consist 3-week treatment cycle progressive disease , unacceptable toxicity , participant 's refusal study treatment . After disease progression , participant follow every 3 month death study cutoff date , whichever come first . The study cut-off date event-driven defined date 873 death occur .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically cytologicallyconfirmed prostate adenocarcinoma ; Metastatic disease ; Progressive disease receive hormonal therapy surgical castration ; Effective castration . Prior cytotoxic chemotherapy prostate cancer , except estramustine except adjuvant/neoadjuvant treatment complete &gt; 3 year ago ; Prior treatment Vascular Endothelial Growth Factor ( VEGF ) inhibitor VEGF receptor inhibitor ; Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
</DOC>